See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Holi
Natural Disasters
Social Media
Baseball
Artificial Intelligence
Senate
Boxing
Stock Markets
Donald Trump
Vladimir Putin
South America
Basketball
Published • loading... • Updated

J&J says its lung cancer drug combination keeps people alive longer

  • Johnson & Johnson reports its lung cancer regimen improves survival by at least a year compared to AstraZeneca's Tagrisso, according to a pivotal trial.
  • The company anticipates annual sales for Rybrevant and Lazcluze could exceed $5 billion, as stated by J&J executives.
  • Researchers from POSTECH and Kyungpook National University developed a new inhalable lung cancer treatment using mucoadhesive protein nanoparticles.
  • Professor Hyung Joon Cha noted that their findings could significantly enhance lung cancer treatment effectiveness and improve patients' quality of life.
Insights by Ground AI
Does this summary seem wrong?

22 Articles

All
Left
1
Center
4
Right
Phys.orgPhys.org

Inhalable therapy uses mussel-inspired nanoparticles to target lung cancer cells

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the adhesive properties of marine mussels.

·United Kingdom
Read Full Article
CNBCCNBC
Reposted by
Daily Expert NewsDaily Expert News

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a year longer than AstraZeneca's Tagrisso.

·United States
Read Full Article
STATSTAT

Johnson & Johnson says its lung cancer drug significantly extended survival

The J&J bispecific antibody, paired with a Janssen drug, has the potential to become standard treatment for non-small lung cancer patients.

·Boston, United States
Read Full Article
BloombergBloomberg

J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.

·United States
Read Full Article
ReutersReuters

J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending lives of patients with a type of lung cancer, compared to AstraZeneca's blockbuster drug Tagrisso.

·United Kingdom
Read Full Article
wmix94.comwmix94.com

SSM Good Samaritan Hospital Invests in Leading-edge Technology for Lung Biopsies

MT. VERNON – SSM Health Good Samaritan Hospital, has invested in minimally invasive options and leading-edge technology for lung biopsies, to deliver life-enhancing care to patients in Southern Illinois. The state-of-the-art endoluminal system is a robotic-assisted platform for minimally invasive biopsy in the lung. This system helps address a challenging aspect of lung biopsy by enabling physicians to obtain tissue samples from deep within the …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 80% of the sources are Center
80% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Reuters broke the news in United Kingdom on Tuesday, January 7, 2025.
Sources are mostly out of (0)

Similar News Topics

Cancer

Cancer

AstraZeneca

AstraZeneca

Johnson & Johnson

Johnson & Johnson

Positive News

Positive News

Stock Markets

Stock Markets

European Union

European Union

Health

Health

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal